Acute respiratory distress syndrome (ARDS) occurs when fluid accumulates in the lungs' elastic air sacs. These air sacs are referred to as alveoli. ARDS is more common in people who have suffered serious injuries or are already critically ill. The main symptom of ARDS is severe shortness of breath, which usually develops within a few hours of the infection or the precipitating injury. Other ARDS symptoms include labored breathing, low blood pressure, confusion, and extreme exhaustion. Hypoxia is a defining feature of acute lung injury (ALI). ALI refers to radiographic and clinical changes that affect the lungs, with ARDH representing the more severe end of the spectrum. CT scans and other imaging techniques are increasingly being used in the diagnosis and management of ARDS. Another modality that can be used as a bedside tool to aid in the diagnosis of ARDS is lung ultrasound. ARDS treatment includes general supportive measures, ventilator strategies, and appropriate underlying condition treatment. Pharmacological interventions, in addition to general supportive measures, are frequently considered throughout ARDS. Even though drug candidates have been studied for over a decade, only a few pharmacological therapies for ARDS have emerged.
The acute respiratory distress syndrome (ARDS) market is being driven by the rising prevalence and incidence of acute lung injury, a diverse set of risk factors for ARDS, and a rapid increase in the patient pool of covid-19 with ARDS. Rising levels of air pollution and lifestyle-related diseases, as well as an increase in accident and trauma-related ARDS, are expected to drive the growth of the global acute respiratory distress syndrome (ARDS) market. Several risk factors, including alcohol abuse, chemotherapy, obesity, and low blood-protein levels, are contributing to an increase in ARDH cases. Furthermore, technological advancements are expected to benefit the market for acute respiratory distress syndrome.
One of the key driving factors of the global market is the availability of appropriate treatment and diagnosis for acute respiratory distress syndrome. Because of the country's increasing technological advancement, the diagnosis segment in the North American region is expected to grow at the fastest rate during the forecast period. The market for acute respiratory distress syndrome stage two, known as the fibroproliferative stage, is expected to grow during the forecasted period. This is because small key players intend to invest in new product research and development.
However, factors such as treatment complications and high device and treatment costs are impeding the growth of the global acute respiratory distress syndrome (ARDS) market. The key market challenge in the global acute respiratory distress syndrome (ARDS) market is the stringent Regulations for approval and multiple challenges faced by ICU nurses.
The Global Acute Respiratory Distress Syndrome Market study provides market data by competitive landscape, revenue analysis, market segments and detailed analysis of key market players such as; Armstrong Medical, ALung Technologies, Inc., Besmed Health Business Corp., BPL medical technologies, Beurer Gmbh, Drägerwerk AG & Co. KGaA, EUROSETS, Fisher & Paykel Healthcare Limited, Fresenius SE & Co. KGaA, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., Getinge AB, Hamilton Medical, LivaNova PLC, Medtronic, Nice Neotech Medical Systems Pvt. Ltd., NIPRO, Pfizer Inc., Terumo Medical Corporation, WEINMANN Emergency Medical Technology GmbH + Co. KG
SPER Market Research study aims to provide market dynamics, demand and supply with yearly forecast to 2030. This report provides data for growth estimates and forecasts for product type segment – By Type [Diagnosis {Imaging testing (Chest X-RAY, CT- scan, Ultrasound, Others), Blood test, Respiratory, SPO2 test, others}, Treatment {Mechanical ventilation (High-flow nasal O2, BI-level positive airway pressure, Continuous positive airway pressure, Prone positive ventilation, others), Corticosteroids (Methylprednisolone, Dexamethasone, Others), Antiviral medication (Remdesivir, Combination drugs, others), Extracorporeal membrane oxygenation, Tocilizumab, Others}], By Cause (Coronavirus disease 2019 (COVID-19), Sepsis, Inhalation of harmful substances, Severe pneumonia, others), By Type {Monitoring devices (Key market trends, growth factors and opportunities, Market size and forecast, Market share analysis), Diagnostic devices (Key market trends, growth factors and opportunities, Market size and forecast, Market share analysis), Therapeutic devices (Key market trends, growth factors and opportunities, Market size and forecast, Market share analysis)}, By Injury {Brain (Key market trends, growth factors and opportunities, Market size and forecast, Market share analysis), Lungs (Key market trends, growth factors and opportunities, Market size and forecast, Market share analysis)}, By Route Of Administration {Parenteral (Intravenous, Intramuscular), Oral, Others}, By End-User Industry (Hospitals, Specialty clinics, Home healthcare, others), By Distribution Channel (Direct tender, Hospital pharmacy, Retail pharmacy, Online pharmacy).
This report also provides the data for key regional segments of North America, Europe, Asia-Pacific and Rest of the World.
This study also encompasses various drivers and restraining factors of this market for the forecast period. Various growth opportunities are also discussed.